About

THE AURON TEAM

A CULTURE OF INNOVATION

Auron was founded by a world class team of physicians and scientists with proven expertise in bringing effective differentiation therapies to patients. Their initial successes highlighted the untapped potential of this transformative approach. Expanding on this knowledge, Auron has built a multi-omic computational platform that has enabled a unique understanding of the dysregulated differentiation pathways in cancer cells and has identified novel drug targets applicable across multiple tumor indications.

David Millan, Ph.D.

Chief Scientific Officer

“Every day I’m inspired by the energy and motivation of our team as we pioneer a new approach to transformative medicines. Our vision is to change the treatment paradigm for a wide range of cancer types for which there are no effective treatment options, and ultimately transform the lives of patients and their families.”

Meet the team

Leadership

Leadership

Kate Yen, Ph.D.

Founder & CEO

David Millan, Ph.D.

Chief Scientific Officer

Thomas Graeber, Ph.D.

Chief Data Officer

Colleen DeSimone
Colleen DeSimone

SVP, Finance

Andrea Armstrong

Chief People Officer

Auron Team

Laura Antipov, Ph.D.

Vice President, Program Management & Operations

Andrea Armstrong

Chief People Officer

Jake Axford
Jake Axford

Principal Scientist

Maulasri Bhatta, PhD
Maulasri Bhatta, Ph.D.

Senior Scientist, II

Mark Bittinger PhD
Mark Bittinger, PhD..

Vice President, Translational Biology

Tori Brown
Tori Brown

Executive Assistant & Operations Manager

Betty Chan, Ph.D.

Director, Biochemistry & Biophysics

Joe DeBartolo, Ph.D.

Senior Director, Data Science

Colleen DeSimone
Colleen DeSimone

SVP, Finance

Thomas Graeber, Ph.D.

Chief Data Officer

Christina Lee
Christina Lee

Senior Scientist, I

David Millan, Ph.D.

Chief Scientific Officer

James Neef

Director, Medicinal Chemistry

Sambad Sharma
Sambad Sharma, Ph.D.

Senior Scientist, II

Roman Shimanovich
Roman Shimanovich Ph.D.

Senior Director, CMC

Sara Yao
Sara Sinicropi-Yao, Ph.D.

Principal Scientist, Translational Biology

Kimberly Straley
Kimberly Straley

Director, Translational Biology

Henry Wilson
Henry Wilson, Ph.D.

Principal Scientist, Computational Biology

Kate Yen, Ph.D.

Founder & CEO

Founders

Ross Levine, M.D.

Memorial Sloan Kettering Cancer Center

Eytan Stein, M.D.

Memorial Sloan Kettering Cancer Center

Matthew Vander Heiden, M.D., Ph.D.

Massachusetts Institute of Technology

Kate Yen, Ph.D.

Founder & CEO

Board of Directors

Anna French
Anna French, Ph.D.

Qiming Venture Partners USA

Eric Gomez
Eric Gomez

Mubadala Capital

Board Observer

Alon Lazarus, Ph.D.

Arkin Bio Ventures

Marianne Mertens
Marianne Mertens, Ph.D.

Apollo Health Ventures

Board Observer

Briggs Morrison, M.D.

Independent Chairman of the Board

Victoria Richon
Victoria Richon Ph.D.

Independent Board Member

Brad Robling

Eli Lilly and Company

Board Observer

Kate Yen, Ph.D.

Founder & CEO

Scientific Advisory Board

Stéphane de Botton, M.D., Ph.D.

Gustave Roussy Cancer Center

Richard Chesworth, Ph.D.

Former CSO, Kymera Therapeutics

Ross Levine, M.D.

Memorial Sloan Kettering Cancer Center

Shin-San Michael Su, Ph.D.

Former CSO, Volastra Therapeutics, Inc.

Mikhail (Misha) Roshal, M.D., Ph.D.

Memorial Sloan Kettering Cancer Center

​Charles Rudin MD PhD
​Charles Rudin, M.D., Ph.D.

​Memorial Sloan Kettering Cancer Center

Kimberly Stegmaier, M.D.

Harvard Medical School and Dana-Farber Cancer Institute

Eytan Stein, M.D.

Memorial Sloan Kettering Cancer Center

George Thomas, M.D.

Oregon Health & Science University

Matthew Vander Heiden, M.D., Ph.D.

Massachusetts Institute of Technology

Investors

These are some of the companies who support our mission:
Apollo Health Ventures
DCVC
Mubadala Capital